At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
Bevacizumab +2 moredrug
Likely dose
Bevacizumab 15mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-armed Phase Ⅱ Study of Bevacizumab Maintenance Therapy After Chemoradiotherapy for Locally Advanced Lung Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating Bevacizumab, chest radiation, and 1 other intervention for Lung Adenocarcinoma. Completed, enrolled 27 participants across 1 site.
Detailed Summary
This prospective phase II study is to determine the efficacy and safety of bevacizumab maintenance therapy after concurrent chemoradiotherapy in locally advanced lung adenocarcinoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Adenocarcinoma
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
First PostedApr 2019
Primary CompletionDec 2021
Study CompletionDec 2022
TodayJul 2026
First PostedApr 5, 2019
Enrollment StartJan 1, 2019
Primary CompletionDec 10, 2021
Study CompletionDec 15, 2022
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 7.2 years ago
Interventions
Bevacizumabdrug
Patients are treated with Bevacizumab 1-2 months after the chemoradiotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.
chest radiationradiation
split-course chest radiation
concurrent chemotherapydrug
weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation